Abstract Details

Title Epidemiological and Demographic Characteristics Related to Social Determinants of Health in Patients with Anti-NMDAR Encephalitis

Topic Autoimmune Neurology

Presentation(s) P5 - Poster Session 5 (11:45 AM-12:45 PM)

Poster/Presentation
Number 6-007

Background Anti-NMDAR encephalitis is a rare neurologic disorder primarily affecting young patients. However, the impact of social determinants of health in anti-NMDA receptor encephalitis are not well-described in the medical literature.

Objective To identify and describe the epidemiological and demographic characteristics related to social determinants of health of patients diagnosed with anti-NMDAR encephalitis in a single center cohort.

Design/Methods A retrospective chart review identified anti-NMDAR encephalitis patients within the University of Utah health system by utilizing the ICD-10 code G04.81 for Other encephalitis and encephalomyelitis or keyword search of “NMDA” between January 2012-August 2022. Of the 212 patients pulled from above, 24 NMDAR encephalitis patients were identified through positive NMDAR IgG antibody assays.

Results

We describe the epidemiological and socioeconomic characteristics of patients with anti-NMDAR encephalitis, including age of onset, presence of antecedent infections or triggers, race and ethnicity, sex, zip code, Gini index, Health Professional Shortage Area (HPSA) designations, duration from symptom onset to diagnosis, insurance type, primary language, and outcome by modified Rankin Score (mRS). We will conduct sensitive analysis on identifying any socioeconomic variables as covariance with the severity of anti-NMDAR encephalitis.

Conclusions

In this cohort, anti-NMDAR encephalitis outcomes were encouraging in the majority of patients. Recognition of specific epidemiologic and demographic related to social determinants of health variables placing anti-NMDAR encephalitis patients at risk for delays in diagnosis and/or underutilization of medical care will benefit this patient population.

Authors/Disclosures
Sarah Shapiro (Kansas City University College of Osteopathic Medicine) PRESENTER	Miss Shapiro has nothing to disclose.
Melissa A. Wright, MD (University of Utah)	Dr. Wright has nothing to disclose.
Trieste Francis	Miss Francis has nothing to disclose.
Sama Noroozi Gilandehi, MD	Dr. Noroozi Gilandehi has nothing to disclose.
Tammy L. Smith, MD, PhD (Imaging and Neurosciences Center)	The institution of Dr. Smith has received research support from Alexion/AstraZeneca. Dr. Smith has received personal compensation in the range of $0-$499 for serving as a attendee with Euroimmun Academy for travel support only.
Ka-Ho Wong (U of U Neurology Clinic)	The institution of Mr. Wong has received research support from The Sumaira Foundation . The institution of Mr. Wong has received research support from The Siegel Rare Neuroimmune Association.
Stacey Clardy, MD, PhD, FAAN (University of Utah)	Dr. Clardy has received personal compensation for serving as an employee of Veterans Health Administration (VHA). Dr. Clardy has received personal compensation for serving as an employee of University of Utah Health. Dr. Clardy has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca/Alexion. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen/Horizon. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyverna. Dr. Clardy has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology/AAN Publications. The institution of Dr. Clardy has received research support from NIH/NINDS. The institution of Dr. Clardy has received research support from SRNA. The institution of Dr. Clardy has received research support from Alexion/AstraZeneca. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a AAN Summer Meeting CoDirector Travel and Lodging with AAN. Dr. Clardy has received personal compensation in the range of $500-$4,999 for serving as a Grand Rounds Travel/Lodging/Honoraria with U of Iowa, Miami, Stanford, Barrow, Beaumont Health, CCF, Emory, Penn State, Mayo Clinic, Walter Reed.